As revealed by our experiments with hepatoma cells exposed to bortezomib along with nelfinavir or salubrinal, an overactivation of the eIF2α–ATF4 pathway perturbs other UPR branches and accelerates cell death. The gene discussed is EIF2A; the disease is hepatocellular carcinoma.